» Articles » PMID: 32148921

Role of Procalcitonin Use in the Management of Sepsis

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2020 Mar 10
PMID 32148921
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Important aspects of sepsis management include early diagnosis as well as timely and specific treatment in the first few hours of triage. However, diagnosis and differentiation from non-infectious causes often cause uncertainties and potential time delays. Correct use of antibiotics still represents a major challenge, leading to increased risk for opportunistic infections, resistances to multiple antimicrobial agents and toxic side effects, which in turn increase mortality and healthcare costs. Optimized procedures for reliable diagnosis and management of antibiotic therapy has great potential to improve patient care. Herein, biomarkers have been shown to improve infection diagnosis, help in early risk stratification and provide prognostic information which helps optimizing therapeutic decisions ("antibiotic stewardship"). In this context, the use of the blood infection marker procalcitonin (PCT) has gained much attention. There is still no gold standard for the detection of sepsis and use of conventional diagnostic approaches are restricted by some limitations. Therefore, additional tests are necessary to enable early and reliable diagnosis. PCT has good discriminatory properties to differentiate between bacterial and viral inflammations with rapidly available results. Further, PCT adds to risk stratification and prognostication, which may influence appropriate use of health-care resources and therapeutic options. PCT kinetics over time also improves the monitoring of critically ill patients with sepsis and thus influences decisions regarding de-escalation of antibiotics. Most importantly, PCT helps in guiding antibiotic use in patients with respiratory infection and sepsis by limiting initiation and by shortening treatment duration. To date, PCT is the best studied biomarker regarding antibiotic stewardship. Still, further research is needed to understand optimal use of PCT, also in combination with other remerging diagnostic tests for most efficient sepsis care.

Citing Articles

PCT-to-albumin ratio and CRP-to-albumin ratio as predictors of febrile neutropenia complications: a prospective observational trial.

Dimitrijevic J, calamac M, durmez O, Stojanovic M Support Care Cancer. 2025; 33(4):262.

PMID: 40064680 DOI: 10.1007/s00520-025-09329-5.


Antibiotic lock therapy for the treatment of peripherally inserted central venous catheter-related bloodstream infection in patients with hematological malignancies: a single center retrospective study.

Zhang Q, Huo Y, Li C, Sun Q, Xi X, Sun R Ann Hematol. 2025; .

PMID: 39998671 DOI: 10.1007/s00277-025-06263-8.


Clinical evaluation of a multiplex droplet digital PCR for diagnosing suspected bloodstream infections: a prospective study.

Peng Y, Xie R, Luo Y, Guo P, Wu Z, Chen Y Front Cell Infect Microbiol. 2025; 14:1489792.

PMID: 39885964 PMC: 11779721. DOI: 10.3389/fcimb.2024.1489792.


Optical Bionanosensors for Sepsis Diagnostics.

Derichsweiler C, Herbertz S, Kruss S Small. 2025; 21(8):e2409042.

PMID: 39745136 PMC: 11855245. DOI: 10.1002/smll.202409042.


The Predictive Value of Absolute Lymphocyte Count and T Cell Subpopulations for Sepsis Prognosis.

Jia X, Li X, Miao L, Bao R, Xiong H, You R Infect Drug Resist. 2024; 17:5215-5227.

PMID: 39619728 PMC: 11607994. DOI: 10.2147/IDR.S480864.


References
1.
Schuetz P, Birkhahn R, Sherwin R, Jones A, Singer A, Kline J . Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med. 2017; 45(5):781-789. PMC: 5389588. DOI: 10.1097/CCM.0000000000002321. View

2.
Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M . Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 2011; 37(5):796-800. PMC: 7080069. DOI: 10.1007/s00134-011-2189-1. View

3.
Becker K, Nylen E, White J, Muller B, Snider Jr R . Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004; 89(4):1512-25. DOI: 10.1210/jc.2002-021444. View

4.
Vincent J, Sakr Y, Sprung C, Ranieri V, Reinhart K, Gerlach H . Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006; 34(2):344-53. DOI: 10.1097/01.ccm.0000194725.48928.3a. View

5.
Iankova I, Thompson-Leduc P, Kirson N, Rice B, Hey J, Krause A . Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis. Crit Care Med. 2017; 46(5):691-698. DOI: 10.1097/CCM.0000000000002928. View